The FDA Voted for 6 Peptides. Its Own Scientists Said No

An FDA advisory committee just voted to open a legal compounding supply line for six of seven peptides, including BPC-157 and TB-500, over the objection of the FDA's own scientists, who recommended against all seven. Dr. Jordan Feigenbaum walks through what the Pharmacy Compounding Advisory Committee actually voted on, why a vote about ulcerative colitis ends up governing tendon and joint use, what the single human BPC-157 trial does and doesn't show, and why "a pharmacy makes it safe" and "there's no money to study it" don't hold up. Evidence-based, no hype, no nocebo.

Timestamps:

| 00:00:00 | The FDA voted 8-6. What it actually means

| 00:01:25 | What I am, and am not, claiming

| 00:03:21 | How they got here: Category 2 and the paperwork

| 00:07:17 | Who was in the room: the panel that flipped

| 00:10:57 | What they voted on: compounding and the bulks list

| 00:15:37 | "No money in it, you can't patent it"

| 00:18:24 | The trials already run: Plevna and MK-677

| 00:22:55 | "I took it and it worked": placebo and fake surgery

| 00:27:02 | The one human trial: Ruenzi 2005

| 00:32:28 | Is it natural? Is it even a drug?